| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Citius Pharmaceuticals (NASDAQ:CTXR) through any online brokerage.
Other companies in Citius Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Citius Pharmaceuticals has a consensus price target of $65.00.
The stock price for Citius Pharmaceuticals (NASDAQ: CTXR) is $0.5037 last updated October 8, 2026 at 8:00 AM EDT.
There are no upcoming dividends for Citius Pharmaceuticals.
Citius Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Citius Pharmaceuticals.
Citius Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
